- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
Pre Clinical CROs Market Real Time Analysis and Forecast 2021–2027 | Key Companies: WuXi AppTec Group , Medpace, Inc. , Pharmaceutical Product Development, LLC , Parexel International , ICON plc , MD Biosciences, Inc., etc
May 03, 2021
North America Antibiotics Market Growth and Trends to 2020-2027 With Top Companies Like Johnson & Johnson Services, Inc, Bristol-Myers Squibb Company, Eli Lilly and Company., Abbott, Pfizer Inc
Dec 09, 2020
Is Hydroxychloroquine Really a Game Changer in the fight against COVID-19?
Apr 15, 2020
Epilepsy Market is expected to reach US$ 10.7 billion by 2030
Feb 14, 2024
Malaria Treatment Market is expected to reach US$ 24,487.73 million by 2030
Nov 02, 2023
AIkido Pharma Adds Artificial Intelligence Leader to Advisory Board
Mar 23, 2020
Pharmaceutical Contract Sales Organizations Market is expected to reach US$ 15,820.86 million by 2030
Oct 11, 2023
Follow us on
